Compare RGNX & CLPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGNX | CLPT |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | United States |
| Employees | N/A | 172 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 528.6M | 554.2M |
| IPO Year | 2015 | 2009 |
| Metric | RGNX | CLPT |
|---|---|---|
| Price | $11.90 | $18.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $28.75 | $20.00 |
| AVG Volume (30 Days) | ★ 2.1M | 871.9K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $10,393,000.00 | ★ $36,971,000.00 |
| Revenue This Year | $51.21 | $45.67 |
| Revenue Next Year | $19.08 | $19.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 126.48 | 17.78 |
| 52 Week Low | $5.46 | $8.27 |
| 52 Week High | $16.19 | $30.10 |
| Indicator | RGNX | CLPT |
|---|---|---|
| Relative Strength Index (RSI) | 79.66 | 64.18 |
| Support Level | $10.75 | $12.55 |
| Resistance Level | $12.05 | $27.64 |
| Average True Range (ATR) | 0.87 | 1.37 |
| MACD | 0.57 | 0.29 |
| Stochastic Oscillator | 96.16 | 74.54 |
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.